Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Kerry Fisher

PhD


Associate Professor

Tumour microenvironment, primary tissue samples and translational science

My research is focused on the tumour microenvironment, notably addressing abnormal metabolism and dysfunctional immune activity.  The structure and composition of tumour stroma can influence disease progression and, crucially, the performance of therapeutic drugs.    Conventional laboratory models do not fully recapitulate the complexity of the tumour microenvironment and our research team makes extensive use of fresh biopsy material from patients.   We have expanded this work to form a live tissue facility for the benefit of the department and our collaborators.

 Translating new therapies to the clinic often involves working with industry, either established companies or new spin-out biotechs from the University.  Over the last 20 years I have been involved in many industrial collaborations in one form or another, helping to manage the development of new treatments from the initial innovation through to science-led clinical trials. 

Recent publications

Hypoxia increases the activity of oncolytic adenoviruses through HIF-2α-stimulated E1A expression.

Journal article

Jacobus EJ. et al, (2026), Signal Transduct Target Ther, 11

T cell engagers: expanding horizons in oncology and beyond.

Journal article

Albayrak G. et al, (2025), Br J Cancer, 133, 1241 - 1249

Deregulation of HLA-I in cancer and its central importance for immunotherapy.

Journal article

Hazini A. et al, (2021), J Immunother Cancer, 9

Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus.

Journal article

Hill C. et al, (2021), Mol Ther Oncolytics, 21, 47 - 61

Tackling HLA Deficiencies Head on with Oncolytic Viruses.

Journal article

Fisher K. et al, (2021), Cancers (Basel), 13

The role of cancer metabolism in defining the success of oncolytic viroimmunotherapy

Journal article

DYER A. et al, (2020), Cytokine and Growth Factor Reviews